Compare IDEXX Laboratories, Inc. (IDXX) vs Unilever plc (UL) Price & Performance

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

Unilever (UL) trades at $61.75, down 1.77% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, but recent quarters have seen EPS misses against expectations. A major development is the planned $65 billion merger with McCormick's food business, expected to close in 2027, which could reshape growth prospects.

Outlook is mixed: robust cash flow and dividend yield near 1.75% support income investors, but execution risks on the McCormick deal and volatile earnings pose challenges. Analysts are divided, with 51% hold ratings, reflecting uncertainty amid strategic shifts. The stock appeals for its defensive staples exposure but requires monitoring of integration progress.